Results 241 to 250 of about 15,828 (290)

Use of abciximab in interventional cardiology

American Heart Journal, 1998
The advent of platelet membrane glycoprotein (GP) IIb/IIIa inhibitors has changed the landscape of interventional cardiology. Given the commercial availability of abciximab and expected regulatory approvals for other receptor blockers, defining appropriate use of these agents in the interventional setting is mandated.
Dietrich C. Gulba, Alec Vahanian, Ben A. van Hout, Håkan Emanuelsson, Amadeo Betriu, Sheldon Goldberg, Nicolas Af Chronos   +6 more
openaire   +4 more sources

Intracoronary or intravenous abciximab after aspiration thrombectomy in patients with STEMI undergoing primary percutaneous coronary intervention.

Cardiovascular Journal of Africa, 2019
OBJECTIVE To test whether aspiration thrombectomy with intracoronary (IC) instead of intravenous (IV) administration of abciximab could reduce the no-reflow phenomenon in patients undergoing primary percutaneous intervention (PCI) for ST-elevation ...
A. Bedjaoui, Karima Allal, M. S. Lounes, Chamseddine Belhadi, Abdelmoumen Mekarnia, Saber Sediki, M. Kara, A. Azaza, J. Monsuez, S. Benkhedda   +9 more
semanticscholar   +1 more source

Possible anaphylactic reaction to abciximab

Catheterization and Cardiovascular Interventions, 1999
We report a patient who experienced a severe anaphylactic reaction during coronary artery stenting. Subsequent to administration of a weight-adjusted dose of abciximab, the patient developed profound hypotension and severe, acute airway obstruction. The reaction was successfully reversed with a 16-hr infusion of epinephrine, steroids, and an H1 blocker.
Joseph A. Guzzo, Timothy C. Nichols
openaire   +3 more sources

In situ administration of abciximab for thrombus resolution during intracranial bypass surgery: case report.

Journal of Neurosurgery, 2018
Abciximab is a glycoprotein IIb/IIIa receptor antagonist that functions to prevent platelet aggregation, thus reducing thrombus initiation and propagation.
Ian A. Buchanan, Brian T. Lee, A. Amar, S. Giannotta   +3 more
semanticscholar   +1 more source

T cell mediated allergy to abciximab

Allergy, 2002
. A NONATOPIC woman, 54 years old, was referred for unstable angina. Coronary angiography revealed critical stenosis for which stenting was indicated, and which was performed under i.v. heparin and abciximab, infused for 12 h. Nine days later the patient underwent a generalized exanthemawith a cervicofacial swelling that persisted for several days.
J. M Vignaud, Gisèle Kanny, Denise-Anne Moneret-Vautrin, Martine Morisset   +3 more
openaire   +3 more sources

αIIbβ3-integrin Ligands: Abciximab and Eptifibatide as Proapoptotic Factors in MCF-7 Human Breast Cancer Cells.

Current Drug Targets, 2015
Integrin receptors are considered to be the key factors in carcinogenesis. αIIbβ3-Integrin (GP IIb/IIIa) is the main glycoprotein of the surface of platelets, its presence has also been noted on the certain cancer cell lines.
J. Konończuk, A. Surażyński, U. Czyżewska, Izabela Prokop, M. Tomczyk, J. Pałka, W. Miltyk   +6 more
semanticscholar   +1 more source

Abciximab: a review and update for clinicians

Expert Review of Cardiovascular Therapy, 2008
The glycoprotein (GP) IIb/IIIa receptor serves as the final common pathway of platelet-thrombus formation. Thus, the GP IIb/IIIa receptor has been identified as a target for the prevention of thrombus formation during acute coronary syndromes and/or percutaneous coronary intervention. While there are several intravenous GP IIb/IIIa inhibitors available,
John J. Young, Ernest L. Mazzaferri
openaire   +2 more sources

Abciximab and fatal pulmonary hemorrhage

Heart & Lung, 2006
Abciximab, a platelet glycoprotein IIb/IIIa receptor blocker, is a well-known agent in percutaneous coronary intervention because of its antiplatelet, antithrombotic effects, which allow for good outcome. Major bleeding is a well-recognized complication of abciximab therapy, and pulmonary hemorrhage, although infrequent, is a serious, under-recognized,
Fahd Rahman, M. Haris U. Usman, Marina Cherayil, Stanley Berger, Humaira N. Adenwalla, Rajesh Venkataraman, Mujeeb Altaf, Manzoor A. Shah, Tasbir ul-Islam, Misbah Baqir   +9 more
openaire   +3 more sources

High-bolus dose tirofiban compared with abciximab in primary percutaneous coronary intervention: a propensity score-matched outcome study.

EuroIntervention, 2015
AIMS The objective of this study was to analyse the outcomes of patients treated with high-bolus dose (HBD) tirofiban compared with abciximab at the time of primary PCI (PPCI) for ST-elevation myocardial infarction (STEMI).
D. Austin, D. Mackay, R. Morley, J. Christie, Barry Hennigan, M. de Belder, J. Pell, K. Oldroyd   +7 more
semanticscholar   +1 more source

Mortality in intracoronary versus intravenous abciximab

The Lancet, 2012
www.thelancet.com Vol 380 July 7, 2012 25 UK (CEC, RST, JLC); Vascular Medicine, Peninsula NIHR Clinical Research Facility and Institute of Biomedical and Clinical Science, Peninsula College of Medicine and Dentistry, University of Exeter, Exeter, UK (ACS); and Peninsula Collaboration for Leadership in Applied Health Research and Care (PenCLAHRC ...
Ankur Gupta, Yash Paul Sharma
openaire   +6 more sources